Dr. Jay Lee, MD
NPI: 1952326654
Total Payments
$366,535
2024 Payments
$111,619
Companies
18
Transactions
284
Medicare Patients
2,230
Medicare Billing
$463,988
Payment Breakdown by Category
Consulting$187,843 (51.2%)
Research$69,565 (19.0%)
Other$66,232 (18.1%)
Travel$36,538 (10.0%)
Food & Beverage$6,357 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $187,843 | 76 | 51.2% |
| Unspecified | $69,565 | 38 | 19.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,232 | 17 | 18.1% |
| Travel and Lodging | $36,538 | 60 | 10.0% |
| Food and Beverage | $6,357 | 93 | 1.7% |
Payments by Type
General
$296,970
246 transactions
Research
$69,565
38 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $69,230 | 47 | $0 (2024) |
| Genentech, Inc. | $60,752 | 27 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $53,472 | 54 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $40,137 | 44 | $0 (2024) |
| F. Hoffmann-La Roche AG | $40,059 | 36 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $31,916 | 15 | $0 (2024) |
| Genentech USA, Inc. | $30,032 | 27 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $24,998 | 15 | $0 (2024) |
| Novartis Pharma AG | $6,495 | 3 | $0 (2022) |
| AstraZeneca UK Limited | $4,296 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $111,619 | 83 | Merck Sharp & Dohme LLC ($60,540) |
| 2023 | $92,945 | 78 | Regeneron Pharmaceuticals, Inc. ($19,795) |
| 2022 | $78,282 | 52 | Genentech, Inc. ($25,633) |
| 2021 | $46,602 | 25 | Genentech, Inc. ($13,388) |
| 2020 | $19,553 | 16 | Genentech, Inc. ($9,214) |
| 2019 | $16,202 | 21 | AstraZeneca Pharmaceuticals LP ($8,519) |
| 2018 | $705.88 | 3 | F. Hoffmann-La Roche AG ($638.60) |
| 2017 | $626.43 | 6 | Genentech, Inc. ($202.30) |
All Payment Transactions
284 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $580.00 | General |
| 11/20/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $7,320.00 | General |
| 11/20/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/06/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $610.00 | General |
| Category: VACCINE | ||||||
| 11/04/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 11/04/2024 | Genentech USA, Inc. | Alecensa (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,540.00 | General |
| Category: BioOncology | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $597.91 | General |
| Category: Oncology | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 10/05/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $91.97 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,150.00 | General |
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $365.91 | Research |
| Study: LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC • Category: BioOncology | ||||||
| 09/27/2024 | Genentech USA, Inc. | Alecensa (Biological) | Food and Beverage | In-kind items and services | $101.66 | General |
| Category: BioOncology | ||||||
| 09/25/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $386.07 | General |
| 09/25/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $68.63 | General |
| 09/25/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $41.18 | General |
| 09/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $9,005.41 | General |
| 09/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 09/09/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 08/27/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,416.50 | General |
| 08/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $826.50 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $7,714.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $6,612.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,222.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC | F. Hoffmann-La Roche AG | $7,375 | 9 |
| CACZ885V2201C | Novartis Pharma AG | $6,495 | 3 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH RESEARCH AGREEMENT | Novartis Pharmaceuticals Corporation | $5,250 | 1 |
| LCMC3 | F. Hoffmann-La Roche AG | $4,107 | 6 |
| CACZ885V2201C-CANOPY-N | Novartis Pharmaceuticals Corporation | $3,424 | 1 |
| PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | F. Hoffmann-La Roche AG | $3,340 | 1 |
| Neoadjuvant targeted therapy in resectable non-small cell lung cancer:nsclc current and future perspectives | F. Hoffmann-La Roche AG | $3,191 | 1 |
| REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN ENSCLC | F. Hoffmann-La Roche AG | $2,563 | 1 |
| PHASE II TRIAL OF NEOADJUVANT AND ADJUVANT CAPMATINIB IN PARTICIPANTS WITH STAGES IB-IIIA, N2 AND SELECTED IIIB (T3N2 OR T4N2) NSCLC WITH MET EXON 14 SKIPPING MUTATION OR HIGH MET AMPLIFICATION (GEOMETRY-N) | Novartis Pharmaceuticals Corporation | $1,371 | 1 |
| Phase II Study of TKIs as Neoadjuvant Therapy in Stage I-III Resectable NSCLC with ALK, ROS1, NTRK, or BRAFV600 Alterations | F. Hoffmann-La Roche AG | $1,141 | 1 |
| THE NEED FOR SURGERY-RELATED ENDPOINTS IN NEOADJUVANT IMMUNOTHERAPY TRIALS IN EARLY STAGE NON-SMALL CELL LUNG CANCER | F. Hoffmann-La Roche AG | $608.01 | 1 |
| NAUTIKA1 previously LCMC4 | F. Hoffmann-La Roche AG | $543.79 | 1 |
| LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC | F. Hoffmann-La Roche AG | $365.91 | 1 |
| PHASE II STUDY OF TKIS AS NEOADJUVANT THERAPY IN STAGE II III RESECTABLE NSCLC WITH ALK, ROS1, NTRK OR BRAF V600 ALTERATIONS | F. Hoffmann-La Roche AG | $143.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 514 | 698 | $1.0M | $109,441 |
| 2022 | 9 | 559 | 753 | $1.2M | $131,132 |
| 2021 | 11 | 609 | 752 | $1.1M | $126,282 |
| 2020 | 12 | 548 | 679 | $950,019 | $97,133 |
Total Patients
2,230
Total Services
2,882
Medicare Billing
$463,988
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 230 | 402 | $385,920 | $47,334 | 12.3% |
| 32663 | Exam of lung with removal of lung lobe using an endoscope | Facility | 2023 | 23 | 23 | $225,596 | $27,064 | 12.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 117 | 117 | $159,120 | $17,935 | 11.3% |
| 32674 | Removal of lymph nodes of chest cavity using an endoscope | Facility | 2023 | 32 | 32 | $44,640 | $5,567 | 12.5% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2023 | 55 | 64 | $115,200 | $3,820 | 3.3% |
| 39402 | Exam of chest with biopsy of lymph node using an endoscope | Facility | 2023 | 13 | 13 | $34,320 | $2,986 | 8.7% |
| 38746 | Removal of lymph nodes of chest cavity and breast bone | Facility | 2023 | 12 | 12 | $16,680 | $2,085 | 12.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 21 | 24 | $13,680 | $1,778 | 13.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 11 | 11 | $9,438 | $871.88 | 9.2% |
| 32663 | Exam of lung with removal of lung lobe using an endoscope | Facility | 2022 | 37 | 38 | $369,158 | $46,340 | 12.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 203 | 373 | $358,080 | $44,142 | 12.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 120 | 120 | $163,200 | $18,456 | 11.3% |
| 32674 | Removal of lymph nodes of chest cavity using an endoscope | Facility | 2022 | 48 | 50 | $69,750 | $8,797 | 12.6% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2022 | 65 | 69 | $124,200 | $4,022 | 3.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 29 | 45 | $10,284 | $3,602 | 35.0% |
| 39402 | Exam of chest with biopsy of lymph node using an endoscope | Facility | 2022 | 15 | 15 | $39,600 | $3,044 | 7.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 31 | 32 | $27,456 | $2,434 | 8.9% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 11 | 11 | $1,067 | $295.40 | 27.7% |
| 32663 | Examination of lung with removal of lung lobe using an endoscope | Facility | 2021 | 31 | 31 | $287,123 | $36,598 | 12.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 157 | 262 | $251,520 | $33,131 | 13.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 125 | 125 | $170,000 | $19,942 | 11.7% |
| 39402 | Examination of chest using an endoscope with lymph node biopsy | Facility | 2021 | 35 | 35 | $92,400 | $8,609 | 9.3% |
| 32674 | Removal of lymph nodes of mid-chest cavity using an endoscope | Facility | 2021 | 36 | 37 | $51,615 | $6,747 | 13.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 53 | 79 | $13,904 | $6,633 | 47.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 63 | 65 | $55,770 | $5,048 | 9.1% |
About Dr. Jay Lee, MD
Dr. Jay Lee, MD is a Thoracic Surgery (Cardiothoracic Vascular Surgery) healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952326654.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jay Lee, MD has received a total of $366,535 in payments from pharmaceutical and medical device companies, with $111,619 received in 2024. These payments were reported across 284 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($187,843).
As a Medicare-enrolled provider, Lee has provided services to 2,230 Medicare beneficiaries, totaling 2,882 services with total Medicare billing of $463,988. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Thoracic Surgery (Cardiothoracic Vascular Surgery)
- Location Los Angeles, CA
- Active Since 07/13/2006
- Last Updated 01/17/2020
- Taxonomy Code 208G00000X
- Entity Type Individual
- NPI Number 1952326654
Products in Payments
- TECENTRIQ (Biological) $48,567
- LIBTAYO (Biological) $34,896
- TAGRISSO (Drug) $24,618
- IMFINZI (Biological) $16,734
- OPDIVO (Biological) $16,606
- ILARIS (Biological) $15,963
- Tecentriq (Biological) $14,574
- Alecensa (Biological) $14,198
- TABRECTA (Drug) $11,204
- FOUNDATIONONE CDX (Device) $1,081
- Non-Covered Product (Drug) $1,055
- IMFINZI (Drug) $537.00
- Da Vinci Surgical System (Device) $213.66
- OSS Orthopedic Salvage System (Device) $198.33
- FLOSEAL (Biological) $158.38
- RibFix Blu (Device) $140.96
- vitagel (Device) $70.83
- HARMONIC Product Family (Device) $57.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Thoracic Surgery (Cardiothoracic Vascular Surgery) Doctors in Los Angeles
Raymond Lee, M.d, M.D
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $279,335
Thoracic Surgery (Cardiothoracic Vascular Surgery) $279,335
Dr. Bryan Burt, M.d, M.D
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $145,854
Thoracic Surgery (Cardiothoracic Vascular Surgery) $145,854
Dr. Harold Tabaie, Md, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $123,837
Thoracic Surgery (Cardiothoracic Vascular Surgery) $123,837
Robbin Cohen, Md, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $115,156
Thoracic Surgery (Cardiothoracic Vascular Surgery) $115,156
Richard Shemin, M.d, M.D
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $107,717
Thoracic Surgery (Cardiothoracic Vascular Surgery) $107,717
Dr. Anthony Kim, Md, MD
Thoracic Surgery (Cardiothoracic Vascular Surgery) — Payments: $67,962
Thoracic Surgery (Cardiothoracic Vascular Surgery) $67,962